|Dr. Michael E. Castagna||CEO & Director||844.2k||N/A||1977|
|Mr. Steven B. Binder||Chief Financial Officer||630.4k||N/A||1963|
|Dr. David B. Thomson||Corp. VP, Gen. Counsel & Sec.||675.97k||N/A||1967|
|Mr. James Patrick McCauley Jr., J.D., M.B.A.||Chief Commercial Officer||614.06k||N/A||1966|
|Mr. Joseph Kocinsky||Chief Technology Officer||N/A||N/A||1964|
|Ms. Rosabel Realica Alinaya||VP of Investor Relations & Treasury||N/A||N/A||1961|
|Dr. Stuart A. Tross||Chief People & Workplace Officer||N/A||N/A||1967|
|Mr. John F. Bedard||Sr. VP of Worldwide Regulatory Affairs||N/A||N/A||1950|
|Mr. Alejandro Galindo M.B.A., M.S.||Chief Commercial Officer||N/A||N/A||N/A|
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension. MannKind Corporation was founded in 1991 and is headquartered in Westlake Village, California.
MannKind Corporation’s ISS Governance QualityScore as of November 1, 2019 is 8. The pillar scores are Audit: 5; Board: 7; Shareholder Rights: 4; Compensation: 9.